NATURE (EnVast as an Adjunct PPCI in Subjects Presenting With STEMI)
Condition(s) studied
Investigational drug(s) / intervention(s)
enVast stent: In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
conventional treatment: Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
Study summary
This study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional intervention.
Eligibility
Primary outcome measure(s)
- Infarct size — At 3 days
size assessed by measurements of CK-MB (U/L)
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| Azienda Ospedaliera Universitaria di Ferrara | Ferrara | Italy | |
| ASST Grande Ospedale Metropolitano Niguarda | Milan | Italy | |
| IRCCS Humanitas Research Hospital | Milan | Italy | |
| University of Rome Tor Vergata | Roma | Italy | |
| Amphia Hospital | Breda | Netherlands | |
| University of Groningen | Groningen | Netherlands | |
| Maasstad Hospital | Rotterdam | Netherlands | |
| University of Bern | Bern | Switzerland | |
| Geneva University Hospitals | Geneva | Switzerland | |
| Luzerner Kantonsspital | Lucerne | Switzerland | |
| Istituto Cardiocentro Ticino | Lugano | Switzerland |
More Vesalio trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04969471 on ClinicalTrials.gov ↗ ← All trials in Italy